Nippon Paint Holdings Co., Ltd. engages in the management and strategies of its group companies that is involved in the manufacture and sale of paints and fine chemicals. The company is headquartered in Osaka, Osaka-Fu and currently employs 38,562 full-time employees. The firm is involved in the manufacture and sale of paint for automobile-, general- and industrial-uses, as well as fine chemicals. The firm operates in four business segments. The Japan segment conducts paint for automobile-, general- and industrial-uses, as well as fine chemicals business. The Asia segment conducts paint for automobile-, general- and industrial-uses, as well as fine chemicals business in China Singapore, Malaysia, Thailand, Korea, Southeast Asian countries, India. The Oceania segment conducts paint business, such as paint for general-, industrial-uses, and paints peripheral businesses. The Americas segment conducts paint for automobile business and contruction coating materials business.
TScan Therapeutics Inc 最大收入来源是 T Cell Receptor-engineered T Cell,在最近的收益报告中收入为 2,816,000。就地区而言, United States 是 TScan Therapeutics Inc 的主要市场,收入为 2,816,000。